 side effects but have the drawback of high costs,
parenteral administration, and at present there is very
limited evidence of the cost effectiveness of PCSK9 inhibitors in people with diabetes, PAD, and a foot ulcer or
gangrene. In addition, the use of these expensive drugs is
a problem for many countries in the world, and for these
reasons a recommendation on LDL level below 1.0 mmol/
L (40 mg/dL) for this speciÔ¨Å